AbbVie Inc. (ABBV) vs ASML Holding N.V. (ASML)

See how AbbVie Inc. and ASML Holding N.V. differ across market data and performance, so you can decide which asset best fits your strategy.

$254.49

NYSE

AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.

View Full Page

$1,747.58

NasdaqGS

View Full Page

Key Metrics Comparison

AbbVie Inc.ABBV

Market Cap

$449.631B

Price

$254.49

24h Change

+0.04%

24h Volume

$5.22M

Employees

57,000

Shares Outstanding

1,768,169,012

ASML Holding N.V.ASML

Market Cap

$671.245B

Price

$1,747.58

24h Change

-2.09%

24h Volume

$2.21M

Employees

43,938

Shares Outstanding

N/A

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

ABBV

40.1%

ASML

59.9%

Volume Share

Share of combined 24h volume

ABBV

70.3%

ASML

29.7%

24h Performance

Price change over last 24 hours

ABBV

0.04%

ASML

-2.09%

Price Comparison

AbbVie Inc.

ASML Holding N.V.